Medistim

Earnings Release • Mar 1, 2023

FOURTH QUARTER & PRELIMINARY YEAR-END RESULTS 2022

FOURTH QUARTER & PRELIMINARY YEAR-END RESULTS 2022

Another record quarter ending at MNOK 141.8 in sales (MNOK 112.7). Full year revenue at MNOK 491.9 (MNOK 427.3) is also a new record, up 15.1 %.

Sales growth is driven by all major geographical regions. Currency neutral sales increase by 21.6 % for the quarter and 11.9 % for the year.

Currency neutral sales of own products increase 24.6 % for the quarter and 14.0 % for the year.

The Vascular business segment grows at 8.8 % for the quarter and 27.3 % for the year.

The Imaging products grows at 33.5 % for the quarter and 44.0 % for the year.

Operating profit (EBIT) for the quarter ended at MNOK 36.5 (MNOK 19.5), with an EBIT margin of 25.7 % (17.3 %). For the year, EBIT ended at MNOK 141.3 (MNOK 116.3), with an EBIT margin of 28.7 % (27.6 %).

The board suggests a dividend of NOK 4.5 (NOK 3.75) per share to the General meeting, a total dividend payout of MNOK 82.1.